MARKET

CCCC

CCCC

C4 Therapeutics, Inc.
NASDAQ
2.950
-0.030
-1.01%
After Hours: 2.930 -0.02 -0.68% 19:57 05/08 EDT
OPEN
2.980
PREV CLOSE
2.980
HIGH
3.075
LOW
2.922
VOLUME
1.35M
TURNOVER
--
52 WEEK HIGH
3.820
52 WEEK LOW
1.210
MARKET CAP
325.03M
P/E (TTM)
-2.3291
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CCCC last week (0427-0501)?
Weekly Report · 4d ago
C4 Therapeutics announces annual shareholder meeting webcast
PUBT · 04/29 11:02
Weekly Report: what happened at CCCC last week (0420-0424)?
Weekly Report · 04/27 10:08
Weekly Report: what happened at CCCC last week (0413-0417)?
Weekly Report · 04/20 10:04
Weekly Report: what happened at CCCC last week (0406-0410)?
Weekly Report · 04/13 10:07
Weekly Buzz: MGNX Resumes LINNET; GSK Wins China Nod; FDA Okays Waters; NBIX Snaps Up SLNO
NASDAQ · 04/10 14:00
Jefferies Remains a Buy on C4 Therapeutics (CCCC)
TipRanks · 04/10 12:56
C4 Therapeutics adopts Massachusetts, Delaware federal courts as exclusive forums for securities suits
Reuters · 04/10 11:18
More
About CCCC
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).

Webull offers C4 Therapeutics, Inc stock information, including NASDAQ: CCCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CCCC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CCCC stock methods without spending real money on the virtual paper trading platform.